Is Drugstore Titan CVS Caremark Still a Good Bet After Taking a Hard Stance Against Tobacco?

Drugstore titan CVS Caremark had people talking in early February after deciding to eliminate tobacco sales in the near future, though the news had limited impact on its stock price. Is the company still a good bet for investors?

Mar 11, 2014 at 2:17PM

Drugstore giant CVS Caremark (NYSE:CVS) made waves in early February after disclosing its intention to forgo tobacco sales starting in October. While some pundits questioned CVS' motives, the policy makes sense for a company that generates the vast majority of sales from health-care products and services. It would likely also help the company stand out in the battle for drug-prescription market share, a fight that pits CVS against mega chains like Walgreen (NASDAQ:WBA) and Rite Aid (NYSE:RAD). So, is a tobacco-less CVS a good bet at current prices?

What's the value?
CVS started out as a chain of discount convenience stores, selling a range of impulse items for on-the-go consumers; items such as carbonated beverages, cigarettes, and personal-care items. While the company had been morphing into a health-care player through the addition of pharmacies to its stores, it made a bold statement about its future direction with the blockbuster purchase of pharmacy-benefits manager Caremark in 2007. The deal significantly increased the company's size and added a benefits-administration franchise that created cross-selling opportunities for its retail operation, much to the chagrin of its competitors.

In FY 2013, CVS continued building on the multi-year growth trajectory for its top line, reporting a 3.2% gain. In its retail segment, growth was achieved thanks to a bump up in the number of prescriptions filled as well as from a continued expansion of its store network; CVS ended the period with more than 7,700 locations. On the downside, though, front-end store sales logged a comparable-store sales decline due to a continued fall in customer-traffic volumes.

Looking into the crystal ball
CVS' management seems to have wisely realized that the company's future doesn't lie in the retail sales of impulse items, an area where the company is anecdotally at a competitive price disadvantage to the mass merchandisers. Instead its future lies in the sale of health-care-related products, primarily pharmaceuticals. 

Long before CVS' new tobacco policy was making headlines, management had been making moves to strength its health-care focus. This involved positioning its pharmacists as trusted health-care advisors, able to counsel consumers on subjects within their sphere of competence, like medication management. CVS has also been adding health-care clinics to a subset of its store base, so-called MinuteClinics, which are staffed with licensed professionals and are capable of performing minor medical treatments.

Not surprisingly, CVS isn't alone in its shift toward a health-care focus, as its major competitors have embarked on similar initiatives. Like CVS, drugstore kingpin Walgreen has been adding health-care clinics to its stores. It has also been opening offsite clinics at worksites of major employers within its geographies, an innovative marketing scheme that puts the company's brand in front of large swaths of employees. 

Walgreen has also been investing heavily in the specialty-pharmacy space. This is highlighted by its acquisition of BioScrip's specialty pharmacy unit in 2012, a niche area that focuses on the most chronically ill members of the population.

Likewise, Rite Aid has been reshaping its chain of drugstores. It is pursuing a nationwide remodeling program that provides for a more open layout and in-store ambassadors who can help consumers navigate their medication-management issues and general health-care concerns. 

Even more so than its competitors, the company has been aggressively pursuing the 65 years of age and older population. It created a loyalty program specifically for that age cohort, the largest purchasers of prescription drugs on a per-capita basis. 

Rite Aid has also been increasing its participation in the wellness-product segment through a long-term partnership with retail-nutrition giant GNC. It's a successful pairing that has added more than 2,000 in-store wellness boutiques to Rite Aid's store base and has allowed it to leverage GNC's popular brand name and product lines.

The bottom line
While perhaps somewhat controversial, CVS' abandonment of tobacco sales makes sense; especially given the company's prominent position in the health-care industry and mission of enabling positive health-care outcomes for its customer base. The three major drugstore chains having already built national store footprints. Therefore, future growth for CVS' retail operation will hinge on an ability to take market share from competitors by differentiating its brand, something it has likely achieved with its policy stance. Even after a strong run over the past 12 months, CVS looks like a long-term winner.

What other winners are out there in the health space?
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.


Robert Hanley owns shares of Rite Aid. The Motley Fool recommends CVS Caremark. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers